Weissbrich B - Search Results

1

Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups.

Weissbrich B, Langmann P, Schubert J, Jassoy C, Klinker H. Weissbrich B, et al. Eur J Med Res. 2003 Nov 12;8(11):495-8. Eur J Med Res. 2003. PMID: 14644704

2

No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.

Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, Weissbrich B. Winzer R, et al. Among authors: weissbrich b. Eur J Med Res. 2003 Dec 9;8(12):531-4. Eur J Med Res. 2003. PMID: 14711599

3

Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.

Benesic A, Zilly M, Kluge F, Weissbrich B, Winzer R, Klinker H, Langmann P. Benesic A, et al. Among authors: weissbrich b. Infection. 2004 Aug;32(4):229-33. doi: 10.1007/s15010-004-3136-7. Infection. 2004. PMID: 15293079 Clinical Trial.

4

Characterization of HIV-specific proliferative T cell responses in HIV-infected persons.

Zhang Y, Huber M, Weissbrich B, Voss G, Langmann P, Klinker H, Jassoy C. Zhang Y, et al. Among authors: weissbrich b. AIDS Res Hum Retroviruses. 2001 May 1;17(7):623-9. doi: 10.1089/088922201300119725. AIDS Res Hum Retroviruses. 2001. PMID: 11375058

5

Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART.

Langmann P, Zilly M, Weissbrich B, Desch S, Väth T, Klinker H. Langmann P, et al. Among authors: weissbrich b. Infection. 2002 Jan;30(1):13-6. doi: 10.1007/s15010-001-1111-0. Infection. 2002. PMID: 11876509

6

Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.

Langmann P, Weissbrich B, Desch S, Väth T, Schirmer D, Zilly M, Klinker H. Langmann P, et al. Among authors: weissbrich b. Eur J Med Res. 2002 Jul 24;7(7):309-14. Eur J Med Res. 2002. PMID: 12176680 Clinical Trial.

7

Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.

Langmann P, Zilly M, Weissbrich B, Schlör C, Väth T, Richter E, Klinker H. Langmann P, et al. Among authors: weissbrich b. Eur J Med Res. 2000 Feb 28;5(2):59-62. Eur J Med Res. 2000. PMID: 10720564 Clinical Trial.

8

Evaluation of drug resistance in HIV infection.

Weissbrich B, Heinkelein M, Jassoy C. Weissbrich B, et al. Adv Virus Res. 2002;58:157-202. doi: 10.1016/s0065-3527(02)58005-2. Adv Virus Res. 2002. PMID: 12205779 Review. No abstract available.

9

No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients.

Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, Weissbrich B. Winzer R, et al. Among authors: weissbrich b. Ann Clin Microbiol Antimicrob. 2005 Jan 20;4:3. doi: 10.1186/1476-0711-4-3. Ann Clin Microbiol Antimicrob. 2005. PMID: 15659247 Free PMC article.

10

Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.

Langmann P, Winzer R, Schirmer D, Heinz W, Leyh M, Guhl C, Weissbrich B, Klinker H. Langmann P, et al. Among authors: weissbrich b. Eur J Med Res. 2008 Oct 27;13(10):469-71. Eur J Med Res. 2008. PMID: 19008174

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters